The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Mashin V.V.

Belova L.A.

Ul'ianovskiĭ gosudarstvennyĭ universitet

Bakhtogarimov I.R.

The Ulyanovsk State University, Ulyanovsk, Russia

Bergelson T.M.

The Ulyanovsk State University, Ulyanovsk, Russia

Sharafutdinova R.R.

The Ulyanovsk State University, Ulyanovsk, Russia

Multicenter observational program for evaluation of the effectiveness of the recognan (citicoline) in the correction of cognitive impairment in patients with chronic cerebrovascular pathology

Authors:

Mashin V.V., Belova L.A., Bakhtogarimov I.R., Bergelson T.M., Sharafutdinova R.R.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(8): 39‑43

DOI: 10.17116/jnevro20171178139-43

Read: 3063 times

Download PDF (RU)
Contact the author
Table of contents

MULTICENTER OBSERVATIONAL PROGRAM FOR EVALUATION OF THE EFFECTIVENESS OF THE RECOGNAN (CITICOLINE) IN THE CORRECTION OF COGNITIVE IMPAIRMENT IN PATIENTS WITH CHRONIC CEREBROVASCULAR PATHOLOGY
MULTICENTER OBSERVATIONAL PROGRAM FOR EVALUATION OF THE EFFECTIVENESS OF THE RECOGNAN (CITICOLINE) IN THE CORRECTION OF COGNITIVE IMPAIRMENT IN PATIENTS WITH CHRONIC CEREBROVASCULAR PATHOLOGY

To cite this article:

Mashin VV, Belova LA, Bakhtogarimov IR, Bergelson TM, Sharafutdinova RR. Multicenter observational program for evaluation of the effectiveness of the recognan (citicoline) in the correction of cognitive impairment in patients with chronic cerebrovascular pathology. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(8):39‑43. (In Russ.)
https://doi.org/10.17116/jnevro20171178139-43

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
A personalized approach to the treatment of chro­nic tension headache and como­rbid mental diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):51-57
Asthenia in the acute period of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3-2):5-10
Comparative study of cognitive impairment in subgroups of bipo­lar affe­ctive diso­rder types I and II, occu­rring with and without psychotic symptoms. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):7-11
Cognitive impairment in asthenic diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):27-32
Rela­tionship between stroke-associated pneumonia and long-term outcomes of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):57-61
Pote­ntial of animal-derived neuropeptides in complex therapy of diabetic neuropathy in patients with type 2 diabetes mellitus. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):83-87
The state of mental health of migrant workers and citi­zens of the Russian Fede­ration: A comparative analysis as illu­strated by the Moscow region. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):95-101
Factors of depression acco­rding to acti­graphy in the fall season. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):27-32
Expe­rience with the use of amitriptyline for chro­nic pelvic pain asso­ciated with endo­metriosis. Russian Journal of Human Reproduction. 2025;(1):86-93
Study of the levo­carnitine effi­cacy for the treatment of mode­rate cognitive impairment in patients with hype­rtension. Russian Journal of Preventive Medi­cine. 2025;(4):45-50
Abstract:

Objective. To study the efficacy and safety of recognan (citicoline) in the treatment of cognitive and depressive disorders in chronic cerebrovascular pathology (chronic brain ischemia) developed in patients with arterial hypertension and/or atherosclerosis. Material and methods. Seven hundred and thirty-six patients with cerebrovascular pathology, cognitive impairment and mild dementia were examined. The sample included 279 (37.9%) men and 457 (62.1%) women aged from 35 to 80 years (mean age 64.5±8.7 years). The drug recognan («Gerofarm», Russia) was administered in the dose of 1000 mg daily during 30 days. Recovery of cognitive functions was assessed with MSSE, correction of visual/spatial coordination with CDT, depression severity with MGDS. Results. The improvement of cognitive function, memory and visual/spatial coordination, decrease in depression severity were observed during the treatment. Conclusion: Recognan reduced cognitive dysfunction and disturbances of visual/spatial coordinationas well as had a positive effect on the emotional sphere decreasing the level of depression.

Keywords:

recognan
citicoline
cognitive impairment
visual/spatial coordination
depression
chronic cerebrovascular pathology
chronic brain ischemia

Authors:

Mashin V.V.

Belova L.A.

Ul'ianovskiĭ gosudarstvennyĭ universitet

Bakhtogarimov I.R.

The Ulyanovsk State University, Ulyanovsk, Russia

Bergelson T.M.

The Ulyanovsk State University, Ulyanovsk, Russia

Sharafutdinova R.R.

The Ulyanovsk State University, Ulyanovsk, Russia

Close metadata

References:

  1. Belova LA, Mashin VV, Nikitin YuM, Belov VG. Gipertonicheskaya entsefalopatiya: kliniko-patogeneticheskie podtipy, klassifikatsiya, diagnostika. Monografiya. Ul’yanovsk: UlGU; 2010. (In Russ.).
  2. Belova LA, Gavrilyuk OV, Mashin VV, Belova NV, Biktimirova KT, Pinkova EA. Antihypertensive therapy influence on clinical and psychological characteristics of patients with hypertensive encephalopathy. Saratov Journal of Medical Scientific Research. 2011;7:4:866-870. (In Russ.).
  3. Levin OS, Golubeva LV. Geterogennost’ umerennogo kognitivnogo rasstroistva: diagnosticheskie i terapevticheskie aspekty. Consilium Medicum. 2006;12:106-110. (In Russ.).
  4. Suslina ZA, Piradov MA, Varakin YuYa, Kadykov AS, Tanashyan MM, Geraskina LA, Shakhparonova NV. Insul’t: diagnostika, lechenie, profilaktika. M.: MEDpress-inform; 2009. (In Russ.).
  5. Suslina ZA, Fonyakin AV, Geraskina LA, Mashin VB, Trunova ES, Mashin VV, Glebov MV. Prakticheskaya kardionevrologiya. Pod red. Suslinoi Z.A., Fonyakina A.V. M.: IMA-PRESS; 2010. (In Russ.).
  6. Mashin VV, Kadykov AS. Gipertonicheskaya entsefalopatiya. Klinika i patogenez (monografiya). Nauchnoe izdanie. Ul’yanovsk. 2002;139. (In Russ.).
  7. Barba R, Martinez-Espinosa S, Rodriguez-Garcia E, Pondal M, Vivancos J, Del Ser T. Poststroke Dementia: Clinical Features and Risk Factors. Stroke. 2000;31:1494-1501. https://doi.org/10.1161/01.str.31.7.1494
  8. Gavrilyuk OV, Mashin VV, Belova LA, Gorbunov VI, Ruzov VI, Nazina LV. Effect of antihypertensive therapy on the life quality of patients with hypertensive encephalopathy. Rehabilitation And Palliative Medicine. 2011;1:28-30. (In Russ.).
  9. Mashin VV, Pinkova EA, Vinokurov LN, Belova LA, Gavrilov VM. Faktory riska pri gipertonicheskoi entsefalopatii i vozmozhnye puti ikh farmakologicheskoi korrektsii. Meditsinskii al’manakh. 2011;1(14):88-90. (In Russ.).
  10. Reis C, Akyol O, Ho WM, Araujo C, Huang L, Applegate RII, Zhang JH. Phase I and Phase II Therapies for Acute Ischemic Stroke: An Update on Currently Studied Drugs in Clinical Research. Biomed Res Int. 2017. https://doi.org/10.1155/2017/4863079
  11. Michael S. Ritsner. Brain Protection in Schizophrenia, Mood and Cognitive Disorders. Springer. 2010;663. https://doi.org/10.1007/978-90-481-8553-5
  12. Hebert R, Lindsay J, Verreault R. Vascular Dementia. Incndence and Risk Factors in the Canadian Study of Health and Aging. Stroke. 2000;5:1487-1493. https://doi.org/10.1161/01.str.31.7.1487
  13. Neary D. Clasification of the dementias. Журнал неврологии и психиатрии. 2000;1:61-67. [Neary D. Clasification of the dementias. Zhurnal nevrologii i psikhiatrii. 2000;1:61-67. https://doi.org/10.1017/s0959259800003725
  14. Roohi-Azizi M, Arabzadeh S, Amidfar M, Salimi S, Zarindast MR, Talaei A, Akhondzadeh S. Citicoline Combination Therapy for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. Clin Neuropharmacol. 2017;40(1):1-5. https://doi.org/10.1097/wnf.0000000000000185
  15. Secades JJ. Citicoline: pharmacological and clinical review, 2016 update. Rev Neurol. 2016;63(03):1-73.
  16. Karsy M, Brock A, Guan J, Taussky P. Neuroprotective strategies and the underlying molecular basis of cerebrovascular stroke. Neurosurg Focus. 2017;42(4):3. https://doi.org/10.3171/2017.1.focus16522
  17. Yuliani S, Widyarini S, Mustofa, Partadiredja G. Turmeric extract inhibits apoptosis of hippocampal neurons of trimethyltin-exposed rats. Bratisl Lek Listy. 2017;118(3):142-148. https://doi.org/10.4149/BLL_2017_028
  18. Secades JJ, Alvarez-Sabín J, Castillo J, Díez-Tejedor E, Martínez-Vila E, Ríos J, Oudovenko N. Citicoline for Acute Ischemic Stroke: A Systematic Review and Formal Meta-analysis of Rand omized, Double-Blind, and Placebo-Controlled Trials. J Stroke Cerebrovasc Dis. 2016;25(8):1984-1996. https://doi.org/10.1016/j.jstrokecerebrovasdis.2016.04.010
  19. Belova LA, Mashin VV. Venoznaja discirkuljacija pri hronicheskih formah cerbrovaskuljarnoj patologii. UlGU; 2015. (In Russ.).
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.